{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IgA+Nephropathy+%28IgAN%29",
    "query": {
      "condition": "IgA Nephropathy (IgAN)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 70,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IgA+Nephropathy+%28IgAN%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T08:15:31.993Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07182227",
      "title": "PS-002 for the Treatment of IgA Nephropathy in Adults",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Immunoglobulin A (IgA) Nephropathy"
      ],
      "interventions": [
        {
          "name": "PS-002",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Purespring Therapeutics Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2026-02",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-03-20",
      "last_synced_at": "2026-05-22T08:15:31.993Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Baltimore, Maryland • Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07182227"
    },
    {
      "nct_id": "NCT06858319",
      "title": "Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Diseases",
        "Kidney Diseases, Chronic",
        "Urological Diseases",
        "Glomerulonephritis",
        "Glomerular Disease",
        "Glomerulonephritis, IGA",
        "Glomerulopathy",
        "Immunoglobulin Disease"
      ],
      "interventions": [
        {
          "name": "zigakibart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 220,
      "start_date": "2025-07-28",
      "completion_date": "2031-06-25",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-05-22T08:15:31.993Z",
      "location_count": 6,
      "location_summary": "Denver, Colorado • Orlando, Florida • Clifton Park, New York + 3 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Clifton Park",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Brentwood",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06858319"
    },
    {
      "nct_id": "NCT07219121",
      "title": "Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Proteinuria",
        "Immunoglobulin A (IgA) Nephropathy",
        "Focal Segmental Glomerulosclerosis",
        "Kidney Transplant"
      ],
      "interventions": [
        {
          "name": "Sparsentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Travere Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-10-07",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-05-22T08:15:31.993Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • New York, New York • Morrisville, North Carolina + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Morrisville",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07219121"
    },
    {
      "nct_id": "NCT04287985",
      "title": "Safety and Efficacy Study of VIS649 for IgA Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunoglobulin A Nephropathy",
        "Glomerular Disease",
        "IgAN"
      ],
      "interventions": [
        {
          "name": "Dose-Placebo",
          "type": "DRUG"
        },
        {
          "name": "Low Dose-VIS649",
          "type": "DRUG"
        },
        {
          "name": "Medium Dose-VIS649",
          "type": "DRUG"
        },
        {
          "name": "High Dose-VIS649",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2020-07-20",
      "completion_date": "2023-06-18",
      "has_results": true,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-05-22T08:15:31.993Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Oxnard, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04287985"
    },
    {
      "nct_id": "NCT02808429",
      "title": "Efficacy and Safety of Atacicept in IgA Nephropathy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgA Nephropathy"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Atacicept 25 mg",
          "type": "DRUG"
        },
        {
          "name": "Atacicept 75 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2017-01-31",
      "completion_date": "2020-02-07",
      "has_results": true,
      "last_update_posted_date": "2021-02-25",
      "last_synced_at": "2026-05-22T08:15:31.993Z",
      "location_count": 16,
      "location_summary": "Glendale, Arizona • Chula Vista, California • Denver, Colorado + 13 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02808429"
    },
    {
      "nct_id": "NCT05174221",
      "title": "A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Disease",
        "Glomerulonephritis"
      ],
      "interventions": [
        {
          "name": "Mezagitamab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2022-11-09",
      "completion_date": "2025-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-05-22T08:15:31.993Z",
      "location_count": 3,
      "location_summary": "Northridge, California • Nampa, Idaho • Evanston, Illinois",
      "locations": [
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Nampa",
          "state": "Idaho"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05174221"
    },
    {
      "nct_id": "NCT07146906",
      "title": "A Study to Assess the Effects of Zigakibart on IgA Nephropathy.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunoglobulin A Nephropathy (IgAN)"
      ],
      "interventions": [
        {
          "name": "zigakibart",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 32,
      "start_date": "2026-03-26",
      "completion_date": "2030-10-18",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-05-22T08:15:31.993Z",
      "location_count": 3,
      "location_summary": "Denver, Colorado • Acworth, Georgia • Edina, Minnesota",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Acworth",
          "state": "Georgia"
        },
        {
          "city": "Edina",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07146906"
    },
    {
      "nct_id": "NCT06983028",
      "title": "Atacicept in Multiple Glomerular Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "pMN",
        "IgAN",
        "Nephrotic Syndrome",
        "MCD",
        "FSGS"
      ],
      "interventions": [
        {
          "name": "Atacicept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vera Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2025-07-07",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-05-22T08:15:31.993Z",
      "location_count": 1,
      "location_summary": "Brisbane, California",
      "locations": [
        {
          "city": "Brisbane",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06983028"
    },
    {
      "nct_id": "NCT06797518",
      "title": "Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glomerulonephritis, IGA",
        "Immunoglobulin A Nephropathy"
      ],
      "interventions": [
        {
          "name": "Iptacopan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 20,
      "start_date": "2025-02-21",
      "completion_date": "2027-11-27",
      "has_results": false,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-05-22T08:15:31.993Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Chubbuck",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06797518"
    },
    {
      "nct_id": "NCT04557462",
      "title": "A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary IgA Nephropathy"
      ],
      "interventions": [
        {
          "name": "LNP023",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 540,
      "start_date": "2021-09-20",
      "completion_date": "2030-12-04",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-05-22T08:15:31.993Z",
      "location_count": 16,
      "location_summary": "Glendale, Arizona • San Diego, California • San Dimas, California + 13 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Dimas",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04557462"
    }
  ]
}